Compare Adaptive Biotechnologies Corp (ADPT) vs iShares MBS ETF (MBB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares MBS ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.24 (market cap $3.33B), while iShares MBS ETF trades at $93.7. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | MBB | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | — |
52-Week High | $22.37 | $96.91 |
52-Week Low | $10.24 | $92.46 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
MBB (iShares MBS ETF) trades at $93.84, down 0.31% with a bearish technical outlook from moving averages. The ETF shows neutral oscillator signals with RSI at 46.40. Recent institutional activity includes mixed positioning changes, with Comerica Bank reducing its stake by 12.9% while Concurrent Investment Advisors increased its position by 75.4% in Q4 2026. The fund focuses on mortgage-backed securities and has maintained consistent dividend payments.
The outlook for MBB remains cautious due to bearish technical signals and mixed institutional sentiment. Investment opportunities include exposure to the real estate sector with a 4% monthly yield potential, though risks involve interest rate sensitivity and mortgage market volatility. The ETF's defensive characteristics may appeal to income-focused investors seeking diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
